The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
Through the arrangement, Paradigm's test, which sequences both DNA and RNA, will be available to the more than 15 million US members in Three River's network.
The tool is aimed at facilitating a simple and efficient process that payors can use to asses a CDx's value and if further technology assessments are warranted.
Stratose and Paradigm have inked a deal providing Stratose's members access to the PCDx test, which uses NGS technology to identify genomic and proteomic mutations.